Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis

Immunological Reviews - Tập 233 Số 1 - Trang 233-255 - 2010
Beatrix Bartók1, Gary S. Firestein2
1Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA 92093, USA.
2Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, USA

Tóm tắt

Summary:  Rheumatoid arthritis (RA) remains a significant unmet medical need despite significant therapeutic advances. The pathogenesis of RA is complex and includes many cell types, including T cells, B cells, and macrophages. Fibroblast‐like synoviocytes (FLS) in the synovial intimal lining also play a key role by producing cytokines that perpetuate inflammation and proteases that contribute to cartilage destruction. Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage. Recent advances in understanding the biology of FLS, including their regulation regulate innate immune responses and activation of intracellular signaling mechanisms that control their behavior, provide novel insights into disease mechanisms. New agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.

Từ khóa


Tài liệu tham khảo

10.1186/ar2669

10.1038/nature01661

10.1016/B978-1-4160-3285-4.10002-6

10.1136/ard.41.2.177

10.1002/art.1780391103

10.1016/B978-1-4160-3285-4.10065-8

10.1084/jem.20041545

10.1126/science.1137306

10.1002/art.1780370211

Morales‐Ducret J, 1992, Alpha 4/beta 1 integrin (VLA‐4) ligands in arthritis. Vascular cell adhesion molecule‐1 expression in synovium and on fibroblast‐like synoviocytes, J Immunol, 149, 1424, 10.4049/jimmunol.149.4.1424

10.4049/jimmunol.167.2.1072

10.1016/B978-1-4160-3285-4.10011-7

10.1002/art.10126

10.1002/art.1780380405

10.1172/JCI118202

Matsumoto S, 1996, Ultrastructural demonstration of apoptosis, Fas and Bcl‐2 expression of rheumatoid synovial fibroblasts, J Rheumatol, 23, 1345

10.4049/jimmunol.164.10.5227

10.1002/art.22853

10.1002/1529-0131(199811)41:11<1979::AID-ART13>3.0.CO;2-C

10.3109/08916939808995367

10.1002/1529-0131(200003)43:3<599::AID-ANR17>3.0.CO;2-T

10.1186/ar69

Firestein GS, 1996, Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium, Am J Pathol, 149, 2143

10.1002/1529-0131(199905)42:5<948::AID-ANR13>3.0.CO;2-L

10.1073/pnas.94.20.10895

10.1073/pnas.152333199

10.1002/1529-0131(199906)42:6<1088::AID-ANR4>3.0.CO;2-E

10.4049/jimmunol.170.4.2214

10.1007/978-1-59745-401-8_24

10.1186/ar1495

10.2353/ajpath.2006.050999

10.1172/JCI114011

Müller‐Ladner U, 1996, Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice, Am J Pathol, 149, 1607

10.1002/path.1711390314

10.1007/s00281-003-0126-2

10.1002/art.20461

10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L

Müller‐Ladner U, 1997, Human IL‐1Ra gene transfer into human synovial fibroblasts is chondroprotective, J Immunol, 158, 3492, 10.4049/jimmunol.158.7.3492

10.1046/j.1365-2249.1998.00508.x

10.1093/rheumatology/39.3.262

Aupperle KR, 1998, Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene, Am J Pathol, 152, 1091

10.1002/1529-0131(200103)44:3<676::AID-ANR117>3.0.CO;2-6

10.1002/art.21099

10.1016/S0002-9440(10)64356-8

10.1186/ar92

10.1002/art.1780400913

10.1002/1529-0131(199810)41:10<1772::AID-ART9>3.0.CO;2-C

10.1186/ar1752

10.1186/ar1448

10.1136/ard.2003.017210

10.1002/ijc.22023

10.1083/jcb.109.2.877

Müller‐Ladner U, 1997, Alternatively spliced CS‐1 fibronectin isoform and its receptor VLA‐4 in rheumatoid arthritis synovium, J Rheumatol, 24, 1873

10.1002/art.24453

Chabaud M, 1998, Enhancing effect of IL‐17 on IL‐1‐induced IL‐6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines, J Immunol, 161, 409, 10.4049/jimmunol.161.1.409

10.1002/art.1780400520

10.1172/JCI119277

10.1038/nbt1412

10.1172/JCI12466

10.1002/art.21919

10.4049/jimmunol.181.5.3252

10.4049/jimmunol.174.10.6424

10.1002/art.22421

10.1002/art.21273

10.1074/jbc.M109.012492

10.1002/art.1780390608

10.4049/jimmunol.168.3.1405

10.1038/nature03417

10.1007/s10495-009-0317-y

10.4161/cbt.4.2.1508

10.4049/jimmunol.169.4.1760

10.4049/jimmunol.175.12.8337

10.1093/rheumatology/39.5.471

10.1159/000060524

10.1093/rheumatology/kem063

10.1002/art.22494

10.1016/j.berh.2006.06.005

10.4049/jimmunol.171.2.1061

10.1074/jbc.M414469200

10.1038/cdd.2009.38

10.1002/art.20680

10.1002/art.21768

10.1073/pnas.0608773104

10.1002/art.21631

10.1186/ar2052

10.4049/jimmunol.162.10.5949

10.4049/jimmunol.164.2.1110

10.1172/JCI11092

10.1042/BJ20090272

10.1002/art.20678

10.1016/S0002-9440(10)63918-1

10.1016/j.cellimm.2005.04.018

10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1

10.1136/ard.2004.025577

10.1002/art.24226

10.1159/000060517

10.1006/clim.2000.4957

10.4049/jimmunol.165.11.6590

10.1111/j.1365-2249.2005.02850.x

10.1186/ar1475

10.1002/art.21140

10.1002/art.21004

10.1093/rheumatology/ken197

10.4049/jimmunol.172.2.1256

10.1016/j.tips.2005.11.001

10.1002/art.23590

10.1186/ar2556

10.1111/j.1582-4934.2002.tb00514.x

10.1172/JCI36389

10.1084/jem.170.3.865

10.1186/ar1026

10.1136/ard.2008.095356

10.1186/ar2107

10.1002/art.1780370507

10.1002/art.20811

10.1126/science.1072682

Han Z, 1999, Jun N‐terminal kinase in rheumatoid arthritis, J Pharmacol Exp Ther, 291, 124

10.1136/ard.2007.074278

10.1093/rheumatology/kem297

10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K

10.1073/pnas.0509188103

10.4049/jimmunol.174.7.4301

10.4049/jimmunol.0900483

10.1186/ar1473

10.1002/art.11228

10.4049/jimmunol.172.3.1612

10.1186/ar2215

10.1002/art.20580

10.1002/art.24887

10.1002/art.20468

10.1093/rheumatology/kem298

10.4049/jimmunol.166.4.2705

10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4

10.4049/jimmunol.174.11.7383

10.1089/hum.2006.17.821

Alten RE, 2009, Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy, Ann Rheum Dis

10.1002/art.24266

10.1002/art.24485

10.1002/art.23992

10.1002/art.24567

10.1124/jpet.105.097436

10.1016/S1357-2725(03)00259-0

Thông tin
Thông tin xuất bản

Immunological Reviews

Tập 233 Số 1

233-255

Thông tin tác giả